Related Experiment Video
Updated: Jul 2, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Impact of the COVID-19 pandemic on cardiovascular mortality and contrast analysis within subgroups
Shoufang Song1, Chen Guo1, Ruiyun Wu1
1Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, Xi'an, China.
Insights
Excess cardiovascular deaths surged during the COVID-19 pandemic, particularly in younger males and minority groups. While mortality rates declined post-2021, the elderly and specific demographics still show persistent excess deaths, highlighting ongoing cardiovascular health disparities.
Area of Science:
- Public Health
- Epidemiology
- Cardiovascular Disease Research
Background:
- The COVID-19 pandemic has been associated with an increase in overall mortality, exceeding deaths directly attributed to SARS-CoV-2 infection.
- Early pandemic data indicated a significant shift in cardiovascular mortality patterns.
- There is a critical need to analyze large-scale cardiovascular mortality data from the pandemic era for effective prevention and control strategies.
Purpose of the Study:
- To analyze cardiovascular disease (CVD) mortality trends from 2010 to 2023.
- To identify and quantify excess cardiovascular deaths during the COVID-19 pandemic (2020-2023) using time series modeling.
- To examine sociodemographic disparities in CVD mortality, including analyses by sex, age, and race/ethnicity.
Main Methods:
- Utilized National Vital Statistics System data from the CDC WONDER platform, employing ICD-10 codes for cardiovascular disease mortality.
- Applied regression analysis to characterize CVD mortality trends (2010-2023) and time series modeling (2010-2019 baseline) to predict and evaluate excess mortality (2020-2023).
- Conducted subgroup analyses based on sex, age, and race/ethnicity to identify specific demographic impacts.
Main Results:
- All-cause age-standardized mortality rates (ASMRs) for CVD significantly increased from 2019 to 2021 (APC 11.27%) and subsequently decreased from 2021 to 2023 (APC -7.0%).
- The most pronounced ASMR changes were observed in Alaska Native/American Indian people, Hispanics, non-Hispanic Black people, the 25-44 age group, and males.
- By 2023, excess deaths remained persistent in the elderly, while the young (25-44) and middle-aged (45-64) cohorts showed no excess deaths; elderly, males, and Alaska Native/American Indian people had the highest proportion of COVID-related excess deaths.
Conclusions:
- Cardiovascular disease mortality saw a notable increase during the early pandemic, followed by a decline, with the most affected groups experiencing the fastest decreases.
- Existing cardiovascular health initiatives demonstrated effectiveness, yet disparities persist.
- Prioritizing further research into cardiovascular healthcare for the elderly and addressing racial disparities is crucial due to observed sociodemographic differences in CVD mortality.
Background:
An increase in deaths has been perceived during the pandemic, which cannot be explained only by COVID-19. The actual number of deaths far exceeds the recorded data on deaths directly related to SARS-CoV-2 infection. Data from early and short-lived pandemic studies show a dramatic shift in cardiovascular mortality. Grounded in the post-pandemic era, macroscopic big data on cardiovascular mortality during the pandemic need to be further reviewed and studied, which is crucial for cardiovascular disease prevention and control.
Methods:
We retrieved and collected data associated with cardiovascular disease mortality from the National Vital Statistic System from the Center for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) platform based on the ICD-10 codes. We applied regression analysis to characterize overall cardiovascular disease mortality trends from 2010 to 2023 and built a time series model to predict mortality for 2020-2023 based on mortality data from 2010 to 2019 in order to affirm the existence of the excess deaths by evaluating observed vs. predicted mortality. We also conducted subgroup analyses by sex, age and race/ethnicity for the purpose of obtaining more specific sociodemographic information.
Results:
All-cause age-standardised mortality rates (ASMRs) for CVD dramatically increased between 2019 and 2021[annual percentage change (APC) 11.27%, p < 0.01], and then decreased in the following 2021-2023(APC: -7.0%, p < 0.01). Subgroup analyses found that the ASMR change was most pronounced in Alaska Indians/Native American people (APC: 16.5% in 2019-2021, -12.5% in 2021-2023, both p < 0.01), Hispanics (APC: 12.1% in 2019-2021, -12.2% in 2021-2023, both p < 0.05) and non-Hispanic Black people (APC:11.8% in 2019-2021, -10.3% in 2021-2023, both p < 0.01)whether during the increasing or declining phase. Similarly, the ASMR change was particularly dramatic for the 25-44 age group (APC:19.8% in 2019-2021, -15.4% in 2021-2023, both p < 0.01) and males (APC: 11.5% in 2019-2021, -7.6% in 2021-2023, both p < 0.01). By the end of 2023, the proportion of COVID-related excess death remained high among the elderly (22.4%), males (42.8%) and Alaska Indians/Native American people(39.7%). In addition, we did not find the presence of excess deaths in the young (25-44) and middle-aged cohort (45-64) in 2023, while excess deaths remained persistent in the elderly.
Conclusions:
All-cause ASMRs for CVD increased notably during the initial two years of the COVID-19 pandemic and then witnessed a decline in 2021-2023. The cohorts (the young, males and minorities) with the steepest rise in mortality decreased at the fastest rate instead. Previous initiatives to promote cardiovascular health were effective, but further research on cardiovascular healthcare for the elderly and racial disparities should be attached to priority considering the presence of sociodemographic differences in CVD death.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Comparing the Survival Analysis of Two or More Groups
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiac Output II: Effect of Stroke Volume on Cardiac Output
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...

